[Relationship between changes in biochemical markers of bone turnover and prediction value of fracture risk].
The change in BMD is poor predictor of vertebral fracture risk after Raloxifene treatment, whereas bone turnover markers were significantly associated with fracture risk. The percent change in osteocalcin (OC) was better able to predict the reduction in vertebral fracture risk than the percent change in femoral neck BMD in patients treated with Raloxifene in MORE study.
Cyaki
Osamu
O
Department of obstetrics and gynecology, Yokohama City University School of Medicine.
D015415:Biomarkers / Q000097:blood; D015519:Bone Density; D001842:Bone and Bones / Q000378:metabolism*; D018849:Controlled Clinical Trials as Topic; D005260:Female; D006801:Humans; D015675:Osteocalcin / Q000097:blood*; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism; D011237:Predictive Value of Tests; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use*; D012306:Risk; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D016103:Spinal Fractures / Q000175:diagnosis* / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome
D015415:Biomarkers; D020845:Selective Estrogen Receptor Modulators; D015675:Osteocalcin; D020849:Raloxifene Hydrochloride